Utilization and toxicity patterns of 2-weekly (Q2W) versus 4-weekly (Q4W) nivolumab for treatment of adjuvant and metastatic melanoma at BC cancer.

Jennifer Truong Shirley S T Yeung Victoria Kletas Mario de LemosKimberly SchaffLynne Nakashima

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)

Q4W dosing is associated with comparable incidence and potentially later onset of IrAEs compared to Q2W dosing. Most IrAEs in both dosing groups were similar and mild. Therefore, Q4W dosing offers a safe alternative to Q2W dosing while providing benefits including decreased workload for staff, decreased clinic visits, and viral exposure by patients.

Keyphrases

risk factors
end stage renal disease
newly diagnosed
chronic kidney disease
primary care
oxidative stress
prognostic factors
peritoneal dialysis
papillary thyroid
squamous cell carcinoma
squamous cell
replacement therapy
smoking cessation